Mounjaro®
Starting from £179.99/mo
Start journey Learn moreGLP-1 weight loss injections are prescription medicines — semaglutide (Wegovy) and tirzepatide (Mounjaro) — that work by mimicking gut hormones your body already produces, reducing appetite and slowing how quickly your stomach empties. In clinical trials, adults using these medicines alongside a reduced-calorie diet lost an average of 15–22% of their body weight over 68–72 weeks. They're not slimming supplements or quick fixes, and in the UK a prescriber must assess your suitability before any supply can be made. That clinical check is the legal requirement and, honestly, the thing that makes them worth taking seriously.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most persistent misconception about GLP-1 weight loss injections is that they're a crutch, that people who use them simply lack the discipline to diet. The biology says otherwise. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases naturally after eating. It signals to your brain that you're full, slows gastric emptying, and helps regulate blood sugar. When a medicine activates those same receptors, the effect isn't manufactured self-control; it's a change in the hormonal signals driving hunger in the first place.
Tirzepatide (Mounjaro) goes a step further, also activating GIP receptors, making it the only dual-agonist weight-loss medicine licensed in the UK. Semaglutide (Wegovy) targets the GLP-1 pathway alone. Both are effective; which suits a given person is a clinical decision, not a marketing one. If you'd like a broader look at how the two compare, our overview of licensed weight loss injections covers the key differences in plain terms.
Worth saying plainly: obesity is a condition shaped by genetics, hormones, environment, and life history. These medicines address some of those biological drivers. That's why the trial results are as significant as they are, and why the NHS now recommends them within defined clinical criteria.
The numbers that circulate on social media often strip out the context. Here's a fairer read. In the SURMOUNT-1 trial (2,539 adults with obesity, no diabetes, 72 weeks), participants using tirzepatide 15mg alongside lifestyle changes lost an average of around 20–21% of body weight. In STEP 1 (the equivalent study for semaglutide 2.4mg) the average was approximately 15% over 68 weeks. Both trials are published in the New England Journal of Medicine, and both were placebo-controlled, randomised studies: proper evidence, not case reports.
Two things worth noting. First, these are averages, some participants lost considerably more, others less. Second, the lifestyle component mattered. Participants received dietary and activity support alongside the medicine; it isn't a treatment you take in isolation. Our page on long-term weight loss with GLP-1 injections goes deeper on what the evidence says about sustained results.
The NHS recommends both medicines for eligible adults. Access on the NHS is phased and the criteria are strict; a growing number of people in the UK access treatment privately through a regulated pharmacy, which is legal, safe when done through the right channels, and doesn't require a GP referral.
The GI side effects (nausea, a tendency toward looser stools early on, occasional constipation as doses increase) are well-documented. What's less widely discussed is that for most people they're temporary. They peak around the first week or two at a new dose level and settle as the body adapts. The slow titration schedule exists precisely to manage this: starting low and moving up gradually, rather than jumping straight to a maintenance dose.
There are side effects that require prompt medical attention. In January 2026 the MHRA issued a Drug Safety Update for GLP-1 medicines specifically highlighting acute pancreatitis, severe stomach pain that may extend to the back, sometimes with vomiting, that doesn't ease. If that happens, stop the injection and get medical help the same day. You can report any suspected side effect via the MHRA Yellow Card scheme.
Injection-site reactions (mild redness, occasional bruising) are common and almost always minor. Rotating sites (abdomen, thigh, upper arm) helps. Some people find that being consistent about timing, whether that's a Sunday evening routine or a quiet Wednesday lunchtime, makes the weekly injection much easier to keep up with. Holidays and bank holidays are worth planning around too: if your usual injection day falls on a day you're travelling, the prescriber or patient information leaflet can advise on a short window for adjustment.
These medicines are not recommended during pregnancy, while breastfeeding, or if you're trying to conceive, and they're not licensed for anyone under 18. Some health conditions, including a personal or family history of medullary thyroid carcinoma, need to be flagged before starting. That's exactly what a thorough consultation is for. Our team's frequently asked questions covers a number of the 'am I suitable?' queries our prescribers hear most often.
Wegovy and Mounjaro are Prescription-Only Medicines. There's no legitimate route to either without a prescriber assessing your health history, current medicines, and weight. That's not bureaucracy, it's the thing that keeps the medicine safe for you specifically.
The NHS route exists, but phased rollout means many people don't currently qualify or face long waiting times. Private prescribing through a GPhC-registered pharmacy is the legal alternative. Before using any online service, check it on the GPhC pharmacy register, any legitimate pharmacy will be listed, and checking takes about thirty seconds. Pens sold via social media, unofficial websites, or with offers of supply without any prescribing process are a genuine safety risk; the MHRA has seized large quantities of counterfeit weight-loss pens in recent years, some containing dangerous substances.
At nume, consultations are reviewed the same day by a named GPhC-registered Independent Prescriber, a real clinician, not automated software. If you're unsure what a private consultation involves, our guide to getting started with a weight loss injection walks through the process step by step, including details on options such as the gl weight loss injection and the ret weight loss injection, so you can see what each involves before deciding. You can also explore the full picture of weight management options before deciding anything.
If cost is a factor in your thinking, our weight loss injection pricing page explains what's included in a legitimate private prescription and what questions to ask any provider. Ready to find out whether you're clinically suitable? Check your eligibility with a free consultation at nume, no obligation, reviewed the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.